Marketplace / Healthtech / Series A
VoxCell BioInnovation
“Advancing drug development through innovative 3D bioprinted tissue models.”
Open round — VoxCell BioInnovation is raising $1.7M for its Series A
The founder is taking investor conversations now, and on PitchSpark you reach them directly — no warm intro, no gatekeeper. Create a free investor account to see the financials and the deck, then message the founder in one click.
Overview
VoxCell BioInnovation is a biotechnology company that develops 3D bioprinted, vascularized human-like tissue models. These models are designed to provide physiologically relevant testing platforms for drug development and oncology research.
Traction
as reported by the founderThe company has established a strategic collaboration with Altasciences, operates a 12,000-square-foot lab facility, and has raised over $10 million in total funding to date.
Traditional drug development often relies on animal models or 2D cell cultures that fail to accurately predict human biological responses, leading to high failure rates and translational gaps.
VoxCell provides ready-to-use, perfusable 3D bioprinted tissue models that replicate native human biology, enabling more predictive and efficient preclinical drug testing.
Company updates
No updates posted yet.
Follow this company
Get an email when VoxCell BioInnovation posts an update. No account needed — one click to unsubscribe.
Achievements
VoxCell BioInnovation — raising $1.7M
Deck · financials · founder contact